{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:32:11Z","timestamp":1794472331203,"version":"4.9.1"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1K08DK114563-01"],"award-info":[{"award-number":["1K08DK114563-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","award":["Research Scholars Award"],"award-info":[{"award-number":["Research Scholars Award"]}],"id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0756-0","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T14:03:28Z","timestamp":1573135408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Budesonide treatment for microscopic colitis from immune checkpoint inhibitors"],"prefix":"10.1136","volume":"7","author":[{"given":"Michael S.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel E.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Fadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-2009","authenticated-orcid":false,"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"issue":"6","key":"756_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"Kristen E. Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol. 2019;40(6):511\u201323.","journal-title":"Trends in Immunology"},{"issue":"2","key":"756_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"1","key":"756_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-cancerbio-030518-055552","volume":"3","author":"M Dougan","year":"2019","unstructured":"Dougan M, Dranoff G, Dougan SK. Cancer immunotherapy: beyond checkpoint blockade. Annual Review of Cancer Biology. 2019;3(1):55\u201375.","journal-title":"Annual Review of Cancer Biology"},{"issue":"4","key":"756_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"756_CR5","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in Cancer therapy. J Clin Oncol. 2015;33(17):1974\u201382.","journal-title":"J Clin Oncol"},{"key":"756_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","volume":"8","author":"M Dougan","year":"2017","unstructured":"Dougan M. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol. 2017;8:1547.","journal-title":"Front Immunol"},{"key":"756_CR7","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u201368.","DOI":"10.1200\/JCO.2017.77.6385"},{"issue":"suppl_4","key":"756_CR8","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119\u201342.","journal-title":"Ann Oncol"},{"issue":"1","key":"756_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"756_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/ibd\/izy104","volume":"24","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24(8):1695\u2013705.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"756_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000278","volume":"3","author":"MH Geukes Foppen","year":"2018","unstructured":"Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3(1):e000278.","journal-title":"ESMO Open"},{"key":"756_CR12","doi-asserted-by":"crossref","unstructured":"Hughes MS, Zheng H, Zubiri L, et al. Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019.","DOI":"10.1002\/cam4.2397"},{"issue":"1","key":"756_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6(1):142.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"756_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Ali FS, Wang X, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7(1):93.","journal-title":"J Immunother Cancer."},{"issue":"15","key":"756_CR15","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2006","unstructured":"Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24(15):2283\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"756_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","volume":"7","author":"YR Badran","year":"2019","unstructured":"Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer. 2019;7(1):226.","journal-title":"J Immunother Cancer"},{"issue":"28","key":"756_CR17","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung Cancer. J Clin Oncol. 2018;36(28):2872\u20138.","journal-title":"J Clin Oncol"},{"issue":"18","key":"756_CR18","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"Alexander T. Faje","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706\u201314.","journal-title":"Cancer"},{"issue":"4","key":"756_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/2326-6066.CIR-16-0302","volume":"5","author":"M Garcia-Neuer","year":"2017","unstructured":"Garcia-Neuer M, Marmarelis ME, Jangi SR, et al. Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in Ipilimumab-treated advanced melanoma patients. Cancer Immunol Res. 2017;5(4):286\u201391.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"756_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","volume":"6","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2018;6(1):95.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"756_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40425-019-0524-1","volume":"7","author":"E Bello","year":"2019","unstructured":"Bello E, Cohen JV, Mino-Kenudson M, Dougan M. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. J Immunother Cancer. 2019;7(1):41.","journal-title":"J Immunother Cancer."},{"issue":"12","key":"756_CR22","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1158\/2326-6066.CIR-17-0659","volume":"6","author":"Y Eshet","year":"2018","unstructured":"Eshet Y, Baruch EN, Shapira-Frommer R, et al. Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study. Cancer Immunol Res. 2018;6(12):1453\u20138.","journal-title":"Cancer Immunol Res."},{"issue":"2","key":"756_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ibd\/izy240","volume":"25","author":"K Choi","year":"2019","unstructured":"Choi K, Abu-Sbeih H, Samdani R, et al. Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis. 2019;25(2):385\u201393.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"756_CR24","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1053\/j.gastro.2018.08.029","volume":"155","author":"KE Burke","year":"2018","unstructured":"Burke KE, Ananthakrishnan AN, Lochhead P, et al. Identification of menopausal and reproductive risk factors for microscopic colitis-results from the Nurses' health study. Gastroenterology. 2018;155(6):1764\u201375 e1762.","journal-title":"Gastroenterology."},{"issue":"1","key":"756_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1053\/j.gastro.2015.11.008","volume":"150","author":"GC Nguyen","year":"2016","unstructured":"Nguyen GC, Smalley WE, Vege SS, Carrasco-Labra A, Committee CG. American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis. Gastroenterology. 2016;150(1):242\u20136 quiz e217\u2013248.","journal-title":"Gastroenterology"},{"issue":"17","key":"756_CR26","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","volume":"15","author":"J Weber","year":"2009","unstructured":"Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591\u20138.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"756_CR27","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"756_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","volume":"10","author":"L Marthey","year":"2016","unstructured":"Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10(4):395\u2013401.","journal-title":"J Crohns Colitis"},{"key":"756_CR29","doi-asserted-by":"crossref","unstructured":"Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology. 2019.","DOI":"10.1111\/his.13963"},{"key":"756_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2018.10.006","volume":"106","author":"A Malet de","year":"2018","unstructured":"de Malet A, Antoni G, Collins M, et al. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer. 2018;106:106\u201314.","journal-title":"Eur J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0756-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0756-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0756-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:38Z","timestamp":1601055938000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0756-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0756-0","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"assertion":[{"value":"25 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient records were accessed and analyzed through a protocol approved by the Partners Institutional Review Board that waved patient consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"V.D. receives research support from Advanced cell Diagnostics and is a consultant for Agios. R.J.S. receives grant funding from Amgen and Merck, and consulting\/advising fees from Amgen, Merck, Novartis, BMS, Array BioPharma, Replimmune, Compugen, Takeda, and Genentech, and a financial relationship with Boehringer Ingelheim. M.D. receives research funding from Novartis, and has received consulting fees from Genentech-Roche, and Tillotts Pharma. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}